Reduction of p53 by Knockdown of the UGT1 Locus in Colon Epithelial Cells Causes an Increase in Tumorigenesis

Cellular and Molecular Gastroenterology and Hepatology

Volumn 2, Issue 1, 2016, Pages 63-76.e5

  Liu, Miao ^a,b   Chen, Shujuan ^a   Yueh, Mei Fei ^a   Wang, Guangji ^b   Hao, Haiping ^b   Tukey, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Colon Cancer; ER Stress; UGT1A

Indexed keywords

BIOLOGICAL MARKER; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SIZE; COLON CARCINOGENESIS; COLON MUCOSA; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; GENE; GENE DELETION; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN CELL; INTESTINE CRYPT; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR GROWTH; UGT1 GENE;

EID: 84952877285     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2015.08.008     Document Type: Article

References (51)

1. Rim S.H., Seeff L., Ahmed F., et al. Colorectal cancer incidence in the United States, 1999-2004: an updated analysis of data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program. Cancer 2009, 115:1967-1976.
2. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Hamilton S.R., Aaltoned L.A.E. World Health Organization classification of tumours. pathology of genetics of tumours of the digestive system 2000, IARC Press, Lyon, France.
4. Butler L.M., Sinha R., Millikan R.C., et al. Heterocyclic amines, meat intake, and association with colon cancer in a population-based study. Am J Epidemiol 2003, 157:434-445.
5. Jamin E.L., Riu A., Douki T., et al. Combined genotoxic effects of a polycyclic aromatic hydrocarbon (B(a)P) and an heterocyclic amine (PhIP) in relation to colorectal carcinogenesis. PLoS One 2013, 8:e58591.
6. Overman M.J., Pozadzides J., Kopetz S., et al. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 2010, 102:144-150.
7. Peters W.H.M., Kock L., Nagengast F.M., et al. Biotransformation enzymes in human intestine: critical low levels in the colon. Gut 1991, 32:408-412.
8. Bergheim I., Bode C., Parlesak A. Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma. BMC Gastroenterol 2005, 5:34.
9. Butler L.M., Duguay Y., Millikan R.C., et al. Joint effects between UDP-glucuronosyltransferase 1A7 genotype and dietary carcinogen exposure on risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1626-1632.
10. Fang J.L., Beland F.A., Doerge D.R., et al. Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 2002, 62:1978-1986.
11. Bushey R.T., Dluzen D.F., Lazarus P. Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism. Drug Metab Dispos 2013, 41:170-179.
12. Hoensch H.P., Roelofs H.M., Edler L., et al. Disparities of conjugating protective enzyme activities in the colon of patients with adenomas and carcinomas. World J Gastroenterol 2013, 19:6020-6025.
13. Giuliani L., Ciotti M., Stoppacciaro A., et al. UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep 2005, 13:185-191.
14. Chen S., Yueh M.F., Bigo C., et al. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci U S A 2013, 110:19143-19148.
15. Strassburg C.P., Manns M.P., Tukey R.H. Differential down regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 1997, 57:2979-2985.
16. Starlard-Davenport A., Lyn-Cook B., Radominska-Pandya A. Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues. Steroids 2008, 73:611-620.
17. Izumi K., Li Y., Ishiguro H., et al. Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen. Mol Carcinog 2014, 53:314-324.
18. Ariyoshi N., Imaoka S., Nakayama K., et al. Comparison of the levels of enzymes involved in drug metabolism between transgenic or gene-knockout and the parental mice. Toxicol Pathol 2001, 29(Suppl):161-172.
19. Hu D.G., Rogers A., Mackenzie P.I. Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway. Mol Pharmacol 2014, 85:887-897.
20. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9:749-758.
21. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
22. Zhang X.P., Liu F., Cheng Z., et al. Cell fate decision mediated by p53 pulses. Proc Natl Acad Sci USA 2009, 106:12245-12250.
23. Tian X.J., Liu F., Zhang X.P., et al. A two-step mechanism for cell fate decision by coordination of nuclear and mitochondrial p53 activities. PLoS One 2012, 7:e38164.
24. Schmitt C.A., Fridman J.S., Yang M., et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002, 1:289-298.
25. Sato T., Vries R.G., Snippert H.J., et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459:262-265.
26. Meley D., Spiller D.G., White M.R., et al. p53-mediated delayed NF-kappaB activity enhances etoposide-induced cell death in medulloblastoma. Cell Death Dis 2010, 1:e41.
27. Rao B., van Leeuwen I.M., Higgins M., et al. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget 2010, 1:639-650.
28. Araki Y., Mukaisyo K., Sugihara H., et al. Increased apoptosis and decreased proliferation of colonic epithelium in dextran sulfate sodium-induced colitis in mice. Oncol Rep 2010, 24:869-874.
29. Dirisina R., Katzman R.B., Goretsky T., et al. p53 and PUMA independently regulate apoptosis of intestinal epithelial cells in patients and mice with colitis. Gastroenterology 2011, 141:1036-1045.
30. Okayasu I., Hatakeyama S., Yamada M., et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98:694-702.
31. Fujii S., Fujimori T., Kawamata H., et al. Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium. Gut 2004, 53:710-716.
32. Chang W.C., Coudry R.A., Clapper M.L., et al. Loss of p53 enhances the induction of colitis-associated neoplasia by dextran sulfate sodium. Carcinogenesis 2007, 28:2375-2381.
33. Sohn O.S., Fiala E.S., Requeijo S.P., et al. Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol. Cancer Res 2001, 61:8435-8440.
34. Tanaka T. Development of an inflammation-associated colorectal cancer model and its application for research on carcinogenesis and chemoprevention. Int J Inflam 2012, 2012:658786.
35. Cribb A.E., Peyrou M., Muruganandan S., et al. The endoplasmic reticulum in xenobiotic toxicity. Drug Metab Rev 2005, 37:405-442.
36. Qu L., Huang S., Baltzis D., Rivas-Estilla A.M., et al. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3β. Genes Dev 2004, 18:261-277.
37. Pluquet O., Qu L.K., Baltzis D., et al. Endoplasmic reticulum stress accelerates p53 degradation by the cooperative actions of Hdm2 and glycogen synthase kinase 3β. Mol Cell Biol 2005, 25:9392-9405.
38. Ferecatu I., Rincheval V., Mignotte B., et al. Tickets for p53 journey among organelles. Front Biosci (Landmark Ed) 2009, 14:4214-4228.
39. He Z., Ma W.Y., Hashimoto T., et al. Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res 2003, 63:4396-4401.
40. Congiu M., Mashford M.L., Slavin J.L., et al. UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 2002, 30:129-134.
41. Langmann T., Moehle C., Mauerer R., et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004, 127:26-40.
42. Kacevska M., Downes M.R., Sharma R., et al. Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism. Clin Cancer Res 2011, 17:3170-3180.
43. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
44. Yamasaki S., Yagishita N., Nishioka K., et al. The roles of synoviolin in crosstalk between endoplasmic reticulum stress-induced apoptosis and p53 pathway. Cell Cycle 2007, 6:1319-1323.
45. Harding H.P., Calfon M., Urano F., et al. Transcriptional and translational control in the Mammalian unfolded protein response. Annu Rev Cell Dev Biol 2002, 18:575-599.
46. Operana T.N., Tukey R.H. Oligomerization of the UDP-glucuronosyltransferase 1A proteins. J Biol Chem 2007, 282:4821-4829.
47. Takeda S., Ishii Y., Mackenzie P.I., et al. Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull 2005, 28:2026-2027.
48. Ishii Y., Takeda S., Yamada H., et al. Functional protein-protein interaction of drug metabolizing enzymes. Front Biosci 2005, 10:887-895.
49. Ishii Y., Takeda S., Yamada H. Modulation of UDP-glucuronosyltransferase activity by protein-protein association. Drug Metab Rev 2010, 42:145-158.
50. Konopnicki C.M., Dickmann L.J., Tracy J.M., et al. Evaluation of UGT protein interactions in human hepatocytes: effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes. Arch Biochem Biophys 2013.
51. Kim E., Deppert W. Interactions of mutant p53 with DNA: guilt by association. Oncogene 2007, 26:2185-2190.